Sandbox/20: Difference between revisions

Jump to navigation Jump to search
Line 80: Line 80:
'''''[[Chloramphenicol]]*''''' ''OR'' '''''[[Ciprofloxacin]]'''''
'''''[[Chloramphenicol]]*''''' ''OR'' '''''[[Ciprofloxacin]]'''''
|-
|-
|'''''[[Escherichia coli|E. coli]], other coliforms, or [[Pseudomonas aeruginosa]] '''''|| ||'''''[[Ceftazidime]] OR [[Cefepime]] 2 gm IV q8h''''' ''PLUS OR NOT'''''''Gentamicin '''''||'''''[[Ciprofloxacin]] 400 mg IV q8–12h'''''; '''''[[Meropenem]] 2 gm IV q8h'''''.
|'''''[[Escherichia coli|E. coli]], other coliforms, or [[Pseudomonas aeruginosa]] '''''|| ||'''''[[Ceftazidime]] OR [[Cefepime]] 2 gm IV q8h''''' <BR> ''PLUS OR NOT'' <BR> '''''[[Gentamicin]] '''''||'''''[[Ciprofloxacin]] 400 mg IV q8–12h'''''; '''''[[Meropenem]] 2 gm IV q8h'''''.
|-
|-
|'''''S. pneumoniae  ''''' || '''''Pen G MIC <0.1 mcg/mL  '''''||''''' Pen G 4 million units IV q4h ''''' ''OR'' '''''[[Ampicillin]] 2 gm IV q4h '''''||
|'''''S. pneumoniae  ''''' || '''''Pen G MIC <0.1 mcg/mL  '''''||''''' Pen G 4 million units IV q4h ''''' ''OR'' '''''[[Ampicillin]] 2 gm IV q4h '''''||
Line 91: Line 91:
|'''''S.pneumoniae '''''||'''''[[Ceftriaxone]]MIC ≥ 1 mcg/mL'''''||'''''[[vancomycin]]  500–750 mg IV q6h'''' ''PLUS'' '''''[[ceftriaxone]]''''' ''OR'''''''[[cefotaxime]]''''' as above)  
|'''''S.pneumoniae '''''||'''''[[Ceftriaxone]]MIC ≥ 1 mcg/mL'''''||'''''[[vancomycin]]  500–750 mg IV q6h'''' ''PLUS'' '''''[[ceftriaxone]]''''' ''OR'''''''[[cefotaxime]]''''' as above)  
||'''''[[Moxifloxacin]] 400 mg IV q24h '''''.'''''If MIC to [[Ceftriaxone]] >2 mcg/mL, add [[Rifampin]] 600 mg 1x/day.'''''
||'''''[[Moxifloxacin]] 400 mg IV q24h '''''.'''''If MIC to [[Ceftriaxone]] >2 mcg/mL, add [[Rifampin]] 600 mg 1x/day.'''''
|-
| '''''[[Pseudomonas aeruginosa]]'''''||  ||'''''[[Cefepime]]''''' ''OR'' '''''[[Meropenem]]'''''||'''''Any 2 of the
following''''': <BR> '''''[[Ciprofloxacin]]''''', '''''[[ Tobramycin]]'''''‡, '''''[[Aztreonam]]'''''
|-
| '''''[[Staphylococcus aureus]]'''''||'''''[[methicillin]]-sensitive''''' ||'''''[[Oxacillin]]'''''||'''''[[Vancomycin]]'''''
|-
| '''''[[Staphylococcus aureus]]'''''||'''''[[methicillin]]-resistant''''' ||'''''[[Vancomycin]]'''''||  ||
|-
| '''''[[Staphylococcus aureus]]'''''||'''''1.[[Coagulase]]-negative''''' <BR> '''''2.'''''[[Oxacillin]]MIC≤0.25'''''||'''''[[Oxacillin]]'''''||'''''[[Vancomycin]]'''''
|-
| '''''[[Staphylococcus aureus]]'''''||'''''1.[[Coagulase]]-negative''''' <BR> '''''2.'''''[[Oxacillin]]MIC>0.25'''''||'''''[[Vancomycin]]'''''||
|-
|-
|
|
|-
|-
|||
|
|-
|}
|}



Revision as of 19:24, 17 December 2013

Bacterial Meningitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Diagnosis

Empiric Therapy

Negative CSF Gram Stain

Group Etiology Preferred Regimen Alternative Regimen
Preterm—1 mo Streptococcus agalactiae (49%)
Escherichia coli (18%)
misc. Gram-positive (10%)
misc. Gram-negative (10%)
Listeria (7%)
Ampicillin
PLUS
Cefotaxime
(for dosage see footnote)
Ampicillin
PLUS
Gentamicin
(for dosage see footnote)
1 mo—50 yrs Streptococcus pneumoniae
Neisseria meningitidis
Haemophilus influenzae
Adult dosage: Cefotaxime 2 gm IV q4—6h OR Ceftriaxone 2 gm IV q12h
PLUS
Vancomycin 500—750 mg IV q6h
PLUS
Dexamethasone
'
Peds'dosage:'Cefotaxime 200 mg/kg per day IV div.q6–8h; Ceftriaxone 100 mg/kg per day IV div. q12h; Vancomycin 15 mg/kg IV q6h.
Meropenem2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity Streptococcus pneumoniae
listeria Gram-negative bacilli
Ampicillin 2 gm IV q4h
PLUS
'Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q6h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Meropenem 2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Post-neurosurgery, post-head trauma, or post-cochlear implant Streptococcus pneumoniae most common, esp. if CSF leak.
Other: Staphylococcus aureus, coliforms, Pseudomonas aeruginosa
Vancomycin (until known not MRSA) 500–750 mg IV q6h2'
PLUS
Cefepime or Ceftazidime 2 gm IV q8h
Meropenem 2 gm IV q8h
PLUS
Vancomycin1 gm IV q6–12h
Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt Staphylococcus epidermidis,Staphylococcus aureus,coliforms,diphtheroids (rare),Propionibacterium acnes Vancomycin 500–750 mg IV q6h
PLUS
Cefepime or Ceftazidime 2 gm IV q8h
Vancomycin 500–750 mg IV q6h
PLUS
Meropenem 2 gm IV q8h
Immuno-compromised Streptococcus pneumoniae ,
'Neisseria meningitidis,
Haemophilus influenzae,
Listeria
Vancomycin
PLUS
Cefepime
PLUS
Ampicillin
Vancomycin
PLUS
TMP/SMX
PLUS
Ciprofloxacin

H. influenzae now very rare, listeria unlikely if young & immuno-competent (add ampicillin if suspect listeria: 2 gm IV q4h)

Children’s dosage 15 mg/kg IV q6h (2x standard adult dose). In adults, max dose of 2-3 gm/day is suggested: 500–750 mg IV q6h.

Postive CSF Gram Stain

Group Etiology Preferred Regimen Alternative Regimen
Gram-positive diplococci S.pneumoniae Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q4–6h
PLUS
Vancomycin 500–750 mg IV q6h
PLUS
timed Dexamethasone 0.15 mg/kg q6h IV x 2–4 days
Meropenem 2 gm IV q8h OR Moxifloxacin 400 mg IV q24h
Gram-negative diplococci N. meningitidis Cefotaxime 2 gm IV q4–6h OR Ceftriaxone 2 gm IV q12h Penicillin G 4 mill. units IV q4h OR Ampicillin 2 gm q4h OR Moxifloxacin 400 mg IV

q24h OR Chloro 1 gm IV q6h

1.>50 yrs 2.alcoholism 3.debilitating assoc diseases 4.impaired cellular immunity Streptococcus pneumoniae
listeriaGram-negative bacilli
Ampicillin 2 gm IV q4h
PLUS
'Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q6h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Meropenem 2 gm IV q8h
PLUS
Vancomycin
PLUS
IV Dexamethasone
Post-neurosurgery, post-head trauma, or post-cochlear implant Streptococcus pneumoniae most common, esp. if CSF leak.
Other:Staphylococcus aureus, coliforms, Pseudomonas aeruginosa
Vancomycin (until known not MRSA) 500–750 mg IV q6h2'
PLUS
Cefepime or Ceftazidime 2 gm IV q8h
Meropenem 2 gm IV q8h
PLUS
Vancomycin1 gm IV q6–12h
Ventriculitis/meningitis due to infected ventriculo-peritoneal (atrial) shunt Staphylococcus epidermidis,Staphylococcus aureus,coliforms,diphtheroids (rare),'Propionibacterium acnes Vancomycin 500–750 mg IV q6h
PLUS
cefepime or ceftazidime 2 gm IV q8h
Vancomycin 500–750 mg IV q6h
PLUS
Meropenem 2 gm IV q8h

Pathogen-Specific Therapy

Bacteria Specific Lab Findings Preferred Regimen Alternative Regimen
Haemophilus influenzae ȕ-lactamase positive Ceftriaxone (peds): 50 mg/kg IV

q12h

Haemophilus influenzae Pen. allergic: Chlorine 12.5 mg/kg IV q6h (max. 4 gm/day.)
Listeria monocytogenes Ampicillin 2 gm IV q4h
PLUS OR NOT
Gentamicin 2 mg/kg loading dose, then 1.7 mg/kg q8h
If pen-allergic, use TMP-SMX 20 mg/kg per day div. q6–12h
Alternative:
1. Meropenem2 gm IV q8h
2. linezolid
PLUS
Rifampin
Neisseria meningitidis Pen. MIC 0.1–1 mcg per mL Ceftriaxone 2 gm IV q12h x 7 days ; if ȕ-lactam allergic, Chlorine 12.5 mg/kg (up to 1 gm) IV q6h Meropenem 2 gm IV q8h OR moxifloxacin 400 mg q24h
Neisseria meningitidis Pen. MIC <0.1 mcg per mL Penicillin OR Ceftriaxone

Chloramphenicol* OR Ciprofloxacin

E. coli, other coliforms, or Pseudomonas aeruginosa Ceftazidime OR Cefepime 2 gm IV q8h
PLUS OR NOT
Gentamicin
Ciprofloxacin 400 mg IV q8–12h; Meropenem 2 gm IV q8h.
S. pneumoniae Pen G MIC <0.1 mcg/mL Pen G 4 million units IV q4h OR Ampicillin 2 gm IV q4h

Ceftriaxone 2 gm IV q12h, Chlorine 1 gm IV q6h

S. pneumoniae 0.1–1 mcg/mL'
Ceftriaxone 2 gm IV q12h OR Cefotaxime 2 gm IV q4–6h
Cefepime 2 gm IV q8h OR Meropenem 2 gm IV q8h
S. pneumoniae ≥2 mcg/mL
vancomycin 500–750 mg IV q6h PLUS ceftriaxone OR''cefotaxime as above) Moxifloxacin 400 mg IV q24h
S.pneumoniae CeftriaxoneMIC ≥ 1 mcg/mL vancomycin 500–750 mg IV q6h' PLUS ceftriaxone OR''cefotaxime as above) Moxifloxacin 400 mg IV q24h .If MIC to Ceftriaxone >2 mcg/mL, add Rifampin 600 mg 1x/day.
Pseudomonas aeruginosa Cefepime OR Meropenem Any 2 of the

following:
Ciprofloxacin, Tobramycin‡, Aztreonam

Staphylococcus aureus methicillin-sensitive Oxacillin Vancomycin
Staphylococcus aureus methicillin-resistant Vancomycin


Staphylococcus aureus 1.Coagulase-negative
2.OxacillinMIC≤0.25
Oxacillin Vancomycin
Staphylococcus aureus 1.Coagulase-negative
2.OxacillinMIC>0.25
Vancomycin

Do's

Don'ts

References


Template:WikiDoc Sources